<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39463416</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A bioanalytically validated RP-HPLC method for simultaneous quantification of rivaroxaban, paracetamol, and ceftriaxone in human plasma: a combination used for COVID-19 management.</ArticleTitle><Pagination><StartPage>25693</StartPage><MedlinePgn>25693</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25693</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75729-y</ELocationID><Abstract><AbstractText>Rivaroxaban is a direct oral anticoagulant medication that has been found to be beneficial for the management of thromboembolic events linked to the Corona virus disease 2019 (COVID-19) pandemic, which has resulted in more than 6 million deaths worldwide. Hence, a sensitive, selective, and green bioanalytically validated method was developed using RP-HPLC coupled with DAD for the simultaneous determination of rivaroxaban in human plasma, and two co-administered drugs, namely, paracetamol, an analgesic, and ceftriaxone, an antibiotic, that are used in the management of COVID-19. An Exsil 100 ODS C18 column (250 × 4.6 mm, 5 μm) was used as the stationary phase, and acetonitrile: water: methanol at a ratio of 60:30:10 (v/v/v) was used in isocratic mode as the mobile phase with a flow rate of 0.7 ml/min. The method was validated over a concentration range of 0.1-10.0 µg/mL for rivaroxaban, and 1.0-15.0 µg/mL for paracetamol and ceftriaxone. The lower limits of detection (LLODs) were found to be 0.03, 0.32, and 0.32 µg/ml for rivaroxaban, paracetamol, and ceftriaxone, respectively. Moreover, the lower limits of quantitation (LLOQs) were found to be 0.1, 0.96, and 0.98 µg/ml. The developed method showed excellent accuracy and precision for the determination of the aforementioned drugs. Four metrics were used to evaluate the greenness of the developed method. The results revealed that the suggested method is green, with values of 81 and 0.6 for the analytical eco-scale and analytical greenness assessment (AGREE), respectively.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Reham A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, 11566, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayad</LastName><ForeName>Miriam F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, 11566, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Lobna A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, 11566, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabik</LastName><ForeName>Yossra A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, 11566, Cairo, Egypt. ytrabik@pharma.asu.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>75J73V1629</RegistryNumber><NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002443" MajorTopicYN="Y">Ceftriaxone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="Y">Rivaroxaban</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="Y">Acetaminophen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056148" MajorTopicYN="N">Chromatography, Reverse-Phase</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>4</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39463416</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75729-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75729-y</ArticleId><ArticleId IdType="pmc">PMC11514257</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harapan, H., Itoh, N.,Yufika,A., et al. Coronavirus disease 2019 (COVID–19): A literature review. J. Infect. Public Health 13(5), 667–673. 10.1016/j.jiph.2020.03.019 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142680</ArticleId><ArticleId IdType="pubmed">32340833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, J., Liang, Z. and Choong, A. The incidence of pulmonary thromboembolism in COVID–19 patients admitted to the intensive care unit: a meta-analysis and meta-regression of observational studies. J. Intensive Care 9(20), 20. 10.1186/s40560-021-00535-x (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897892</ArticleId><ArticleId IdType="pubmed">33618760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli, B., Madhavan, M., Jimenez, D., et al. COVID–19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75 (23), 2950–2973. 10.1016/j.jacc.2020.04.031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID–19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID–19) Treatment Guidelines. National Institutes of Health.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal, N., Yu, Y., Chen, Y., et al. Paracetamol is associated with a lower risk of COVID–19 infection and decreased ACE2 protein expression: A retrospective analysis. COVID 1, 218–229. 10.3390/covid1010018 (2021).</Citation></Reference><Reference><Citation>Adebisi, Y., Jimoh, N., Ogunkola, I., et al., The use of antibiotics in COVID–19 management: a rapid review of national treatment guidelines in 10 African countries. Trop. Med. Health 49(1), 51. 10.1186/s41182-021-00344-w (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220112</ArticleId><ArticleId IdType="pubmed">34162445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lories, I., Mostafa, A. and Girges,M., High performance liquid chromatography, TLC densitometry, first derivative and first derivative ratio spectrophotometry for determination of rivaroxaban and its alkaline degradates in bulk powder and its tablets. J. Chromatogr. Sep. Tech.., 4(8), 1–6. 10.4172/2157-7064.1000202 (2013).</Citation></Reference><Reference><Citation>Schmitz, E., Boonen, K., van den Heuvel, D., et al., Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J. Thromb. Haemost. 12(10), 1636–1646. 10.1111/jth.12702 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25142183</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal, M., Khalil, N., Imam, F. et al., A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. J. Thromb. Haemost. 39, 79–88. DOI: 10.1007/s11239-014-1121-2 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25106734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde, G., Determination of rivaroxaban – a novel, oral, direct factor xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry. J. Chromatogr. B, 872(1–2), 43–50. DOI: 10.1016/j.jchromb.2008.07.015 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18675600</ArticleId></ArticleIdList></Reference><Reference><Citation>Korostelev, M., Bihan, K., Ferreol, L., et al., Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography–tandem mass spectrometry. J. Pharm. Biomed. Anal. 100, 230–235. 10.1016/j.jpba.2014.08.011 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25173108</ArticleId></ArticleIdList></Reference><Reference><Citation>Çelebier, M., Reçber, T., Koçak, E., et al., Determination of rivaroxaban in human plasma by solid-phase extraction–high performance liquid chromatography.J. Chromatogr. Sci., 54(2), 216–220. 10.1093/chromsci/bmv135 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26351327</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Obaidy, S., Li-Wan-Po, A., McKiernan, P., et al., Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. J. Pharm. Biomed. Anal. 13(8), 1033–1039. 10.1016/0731-7085(95)01303-3 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8580148</ArticleId></ArticleIdList></Reference><Reference><Citation>Senyuva, H. and Ozden, T., Simultaneous high-performance liquid chromatographic determination of paracetamol, phenylephrine HCl, and chlorpheniramine maleate in pharmaceutical dosage forms. J. Chromatogr. Sci. 40(2), 97–100. 10.1093/chromsci/40.2.97 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11881712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaralli, B., Jaldappa, S., Babu, G., et al., Liquid chromatographic determination of ceterizine hydrochloride and paracetamol in human plasma and pharmaceutical formulations. Anal. Technol. Biomed Life Sci. 798(1), 49–54. DOI: 10.1016/j.jchromb.2003.08.048 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14630358</ArticleId></ArticleIdList></Reference><Reference><Citation>Delvadiya, K., Kapara, P., Kimbahune, R., et al., High-performance liquid chromatographic determination of paracetamol, propyphenazone, and caffeine in pharmaceutical formulations Indian. J. Pharm. Educ. Res. 47(4), 65–72. 10.5530/ijper.47.4.9 (2014).</Citation></Reference><Reference><Citation>Kam, R., Chan, M., Ghose, A., et al., Quantitation of paracetamol by liquid chromatography-mass spectrometry in human plasma in support of clinical trial. Future Sci. OA 4 (8), FSO331. 10.4155/fsoa-2018-0039 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6153454</ArticleId><ArticleId IdType="pubmed">30271617</ArticleId></ArticleIdList></Reference><Reference><Citation>Dargue, R., Grant, I., Nye, L., et al., The analysis of acetaminophen (paracetamol) and seven metabolites in rat, pig and human plasma by U(H)PLC-MS. Bioanalysis 12(7), 485–500. 10.4155/bio-2020-0015 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32343149</ArticleId></ArticleIdList></Reference><Reference><Citation>Demotes-Mainard, F., Vinçon, G., Jarry, C., et al., Micromethod for determination of ceftriaxone in plasma and urine by high-performance liquid chromatography. J. Pharm. Biomed. Anal., 6(4), 407–413. 10.1016/0731-7085(88)80006-2 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">16867407</ArticleId></ArticleIdList></Reference><Reference><Citation>Eric-Jovanovic, S., Agbaba, D., Zivanov-Stakic, D,. et al. HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms. J. Pharm. Biomed. Anal., 18(4), 893–898. 10.1016/S0731-7085(98)00274-X (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9919994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotani, A., Hirai, J., Hamada, Y., et al., Determination of ceftriaxone concentration in human cerebrospinal fluid by high-performance liquid chromatography with UV detection. J. Chromatogr. B 1124, 161–164. 10.1016/j.jchromb.2019.06.008 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31202181</ArticleId></ArticleIdList></Reference><Reference><Citation>Narimani, S. and Samadi, N., Rapid trace analysis of ceftriaxone using new fluorescent carbon dots as a highly sensitive turn-off nanoprobe. Microchem. J. 168, 106372. 10.1016/j.microc.2021.106372 (2021).</Citation></Reference><Reference><Citation>Xiao, C., Zhang, X., Wang, W., et al., Developing an improved UHPLC method for impurity profile analysis of ceftriaxone using analytical quality by design. Anal. Methods 15(5), 639–647. DOI: 10.1039/D2AY02016E (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36651613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioanalytical Method Validation Guidance for Industry. Food and Drug Administration, HHS., 83(99), 23690–23691 (2018).</Citation></Reference><Reference><Citation>Selimoğlu, F. and Pinarcik, N., Spectrophotometric quantification of paracetamol and tramadol hydrochloride by chemometric calibration methods. Turk. J. Chem. 47(3), 633–645. 10.55730/1300-0527.3566 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10387862</ArticleId><ArticleId IdType="pubmed">37529219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabré, M., Ferey, L., Somé, I., et al., Greening reversed-phase liquid chromatography methods using alternative solvents for pharmaceutical analysis. Molecules 23(5), 1065. 10.3390/molecules23051065 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6100308</ArticleId><ArticleId IdType="pubmed">29724076</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Maraghy, C. and Lamie, N., Three smart spectrophotometric methods for resolution of severely overlapped binary mixture of Ibuprofen and Paracetamol in pharmaceutical dosage form. BMC Chem. 13(1), 99. DOI: 10.1186/s13065-019-0618-3 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6683492</ArticleId><ArticleId IdType="pubmed">31406964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodipyaka, S., Pola, R., Yenumula, P., et al., Development and validation of bio-analytical method for the quantitative estimation of rivaroxaban by using UV spectrophotometry. World J. Pharm. Sci. 8(2), 38–43 (2020).</Citation></Reference><Reference><Citation>Dew, L., Djoko Wahyono, D., Puspitasari, I., et al., Validation of simple spectrophotometric method for determination of ceftriaxone in human plasma. Int. J. Res. Pharm. Sci 11((SPL 4)), 1645–164.9. 10.26452/ijrps.v11iSPL4.4351 (2020).</Citation></Reference><Reference><Citation>Tsai, T., Cheng, F., Hung, L., et al., Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography. Int. J. Pharm., 193(1), 21–26. 10.1016/S0378-5173(99)00309-9 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10581418</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance, R., Validation of Chromatographic Methods. Center for Drug Evaluation and Research (CDER), 1994. 2</Citation></Reference><Reference><Citation>Ahmed, A., Gamal, M., Naguib, I., et al., Environmental impact of the reported chromatographic methods for the determination of the first FDA-Approved therapy for COVID–19 Patients, Remdesivir: A comparative study. Microchem. J. 176, 107242. 10.1016/j.microc.2022.107242 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801062</ArticleId><ArticleId IdType="pubmed">35125520</ArticleId></ArticleIdList></Reference><Reference><Citation>Keith, L., Gron, L. and Young, J., Green analytical methodologies. Chem. Rev. 107(6), 2695–2708. 10.1021/cr068359e (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17521200</ArticleId></ArticleIdList></Reference><Reference><Citation>Code of Federal Regulations, Protection of Environment, Identification and Listing of Hazardous Waste, Environmental Protection Agency (EPA) ( 2016).</Citation></Reference><Reference><Citation>Płotka-Wasylka, J., A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta 181, 204–209. 10.1016/j.talanta.2018.01.013 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426502</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabik, Y., Ismail, R., Farid, M., et al. Microfabricated potentiometric sensor based on a carbon nanotube transducer layer for selective Bosentan determination. Rev. Anal. Chem., 43(1). 10.1515/revac-2023-0071 (2024).</Citation></Reference><Reference><Citation>Pena-Pereira, F., Wojnowski, W. and Tobiszewski, M., AGREE—Analytical GREEnness metric approach and software. Anal. Chem., 92(14), 10076–10082. 10.1021/acs.analchem.0c01887 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588019</ArticleId><ArticleId IdType="pubmed">32538619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamal, M., Naguib, A., Pada, D., et al., Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. Anal. Methods 13(3), 369–380. DOI: 10.1039/D0AY02169E (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">33404016</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>